In The Lancet Oncology, Robert Coleman and colleagues report that the addition to adjuvant therapy of an intensive treatment with denosumab (120 mg subcutaneously every 3–4 weeks and then every 12 weeks for 5 years) in the D-CARE trial does not improve clinically significant outcomes of patients with early breast cancer. Moreover, 122 (5%) of the 2241 patients receiving denosumab had osteonecrosis of the jaw, which had not resolved by data cutoff in more than half of the cases.

中文翻译：

---

地诺单抗在早期乳腺癌中的作用：阴性数据和行动呼吁。

在《柳叶刀肿瘤》杂志中，Robert Coleman及其同事报告说，在D-CARE试验中，除了补充辅助治疗中使用地诺单抗的强化治疗（每3–4周皮下注射120 mg，然后每12周治疗5年）在临床上没有改善早期乳腺癌患者的重要结局。此外，接受地诺单抗的2241例患者中有122例（5％）颌骨骨坏死，超过一半的病例没有通过数据切除解决。